Science Advances: JAK inhibitor Baricitinib reduces death rate in patients with new crown COVID-19 by 71%

A study by Karolinska Institutet in Sweden found that the rheumatoid arthritis drug JAK inhibitor Baricitinib blocked virus invasion and reduced mortality in patients with moderate to severe COVID-19.
the study, published in the journal Science Advances, supports the continuation of ongoing clinical trials.
, who co-authored the study, said: "The mortality rate for new crown patients receiving the Baricitinib joint standard treatment decreased by 71 per cent.
are particularly encouraging because of the large number of elderly patients involved in this study.
" in this study, 83 patients hospitalized with COVID-19 pneumonia received standard treatment with Baricitinib, of which 16.9 percent died or needed invasing mechanical aeration.
compared with 34.9 per cent of the 83 patients who received standard treatment alone.
the patient's middle age was 81.
researchers say the drug is well-to-do from day one and can reduce inflammation.
previous studies have reported that side effects of long-term use of Baricitinib, including clotting disease and thrombosis, are not apparent in any patients and may be due to the use of anticoagulant medication.